JPMorgan Chase & Co. Boosts Stock Holdings in Haleon PLC Sponsored ADR $HLN

JPMorgan Chase & Co. lifted its position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 15.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,776,686 shares of the company’s stock after acquiring an additional 1,174,813 shares during the period. JPMorgan Chase & Co. owned approximately 0.20% of Haleon worth $91,014,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC purchased a new position in shares of Haleon in the fourth quarter worth $187,000. AE Wealth Management LLC increased its holdings in Haleon by 6.5% in the 1st quarter. AE Wealth Management LLC now owns 19,323 shares of the company’s stock worth $199,000 after buying an additional 1,186 shares in the last quarter. Cetera Investment Advisers raised its position in Haleon by 17.8% in the 1st quarter. Cetera Investment Advisers now owns 164,390 shares of the company’s stock worth $1,692,000 after buying an additional 24,876 shares during the last quarter. Assetmark Inc. lifted its stake in Haleon by 895.7% during the 1st quarter. Assetmark Inc. now owns 19,387 shares of the company’s stock valued at $199,000 after acquiring an additional 17,440 shares during the period. Finally, Pacer Advisors Inc. lifted its stake in Haleon by 10.5% during the 1st quarter. Pacer Advisors Inc. now owns 37,311 shares of the company’s stock valued at $384,000 after acquiring an additional 3,532 shares during the period. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HLN has been the subject of several research reports. The Goldman Sachs Group raised shares of Haleon from a “neutral” rating to a “buy” rating in a report on Wednesday, September 10th. Barclays lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, September 16th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $12.33.

Haleon Stock Down 0.7%

HLN opened at $9.76 on Friday. The firm’s 50 day simple moving average is $9.29 and its two-hundred day simple moving average is $9.86. The company has a market capitalization of $43.44 billion, a PE ratio of 25.01, a PEG ratio of 2.99 and a beta of 0.20. Haleon PLC Sponsored ADR has a 1-year low of $8.71 and a 1-year high of $11.42. The company has a current ratio of 0.87, a quick ratio of 0.63 and a debt-to-equity ratio of 0.48.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.